Table 1.
ZIKV Vaccine Candidates in Clinical Development
| Vaccine Strategy | Platform | Sponsor | Candidate Name | Immunogen | Phase 1 | Phase 2 |
|---|---|---|---|---|---|---|
| Nucleic acid | DNA | GeneOne Life Sciences | GLS-5700 | prME | June 2016: NCT0280944;3 August 2016: NCT02887482 | |
| VRC/NIAID | VRC5288 | prME | August 2016: NCT02840487 | |||
| VRC/NIAID | VRC5283 | prME | December 2016: NCT02996461 | 2a—March 2017; 2b—July 2017: NCT03110770 | ||
| mRNA | Moderna Therapeutics | mRNA-1325 | prME | Phase 1/2—December 2016: NCT03014089 | ||
| Whole inactivated | Formalin inactivated | WRAIR/BIDMC | ZPIV | Whole virus | November 2016: NCT02963909; October 2016: NCT0295283; October 2016: NCT02937233; February 2017: NCT03008122 | |
| Bharat Biotech International | Purified inactivated ZIKV | Whole virus | May 2017 | |||
| Vector based | Measles virus vector | Themis Bioscience | MV-Zika | prME | April 2017: NCT02996890 | |
Abbreviations: BIDMC, Beth Israel Deaconess Medical Center; NIAID, National Institute of Allergy and Infectious Diseases; VRC, Vaccine Research Center; WRAIR, Walter Reed Army Institute of Research; ZIKV, Zika virus; ZPIV, ZIKV purified inactivated virus.